Patents by Inventor Brian Springthorpe

Brian Springthorpe has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TRISUBSTITUTED TRIAZOLOPYRIMIDINES FOR USE IN PLATELET AGGREGATION INHIBITION
    Publication number: 20150152111
    Abstract: The invention provides new triazolo[4,5-d]pyrimidine compounds, their use as medicaments, compositions containing them and processes for their preparation.
    Type: Application
    Filed: June 20, 2014
    Publication date: June 4, 2015
    Applicant: AstraZeneca UK Limited
    Inventors: David Hardern, Anthony Ingall, Brian Springthorpe, Paul Willis, Simon Guile
  • TRISUBSTITUTED TRIAZOLOPYRIMIDINES FOR USE IN PLATELET AGGREGATION INHIBITON
    Publication number: 20140296258
    Abstract: The invention provides new triazolo[4,5-d]pyrimidine compounds, their use as medicaments, compositions containing them and processes for their preparation.
    Type: Application
    Filed: October 31, 2013
    Publication date: October 2, 2014
    Applicant: AstraZeneca UK Limited
    Inventors: David Hardern, Anthony Ingall, Brian Springthorpe, Paul Willis, Simon Guile
  • TRISUBSTITUTED TRIAZOLOPYRIMIDINES FOR USE IN PLATELET AGGREGATION INHIBITION
    Publication number: 20130072503
    Abstract: The invention provides new triazolo[4,5-d]pyrimidine compounds, their use as medicaments, compositions containing them and processes for their preparation.
    Type: Application
    Filed: March 19, 2012
    Publication date: March 21, 2013
    Applicant: AstraZeneca
    Inventors: David Hardern, Anthony Ingall, Brian Springthorpe, Paul Willis, Simon Guile
  • NOVEL PIPERIDINE DERIVATIVES
    Publication number: 20130023562
    Abstract: The present invention provides a compound of a formula (I): wherein the variables are defined herein; to a process for preparing such a compound; and to the use of such a compound in the treatment of a chemokine (such as CCR3) mediated disease state.
    Type: Application
    Filed: July 27, 2012
    Publication date: January 24, 2013
    Applicant: ASTRAZENECA AB
    Inventors: Talbir Austin, David O'Sullivan, Matthew Perry, Brian Springthorpe
  • Piperidine derivatives
    Patent number: 8314127
    Abstract: The present invention provides a compound of a formula (I): wherein the variables are defined herein; to a process for preparing such a compound; and to the use of such a compound in the treatment of a chemokine (such as CCR3) mediated disease state.
    Type: Grant
    Filed: July 19, 2006
    Date of Patent: November 20, 2012
    Assignee: Astrazeneca AB
    Inventors: Talbir Austin, David O'Sullivan, Matthew Perry, Brian Springthorpe
  • Novel compounds
    Publication number: 20120165348
    Abstract: The invention provides new triazolo[4,5-d]pyrimidine compounds, their use as medicaments, compositions containing them and processes for their preparation.
    Type: Application
    Filed: July 21, 2011
    Publication date: June 28, 2012
    Applicant: AstraZeneca AB
    Inventors: David Hardern, Anthony Ingall, Brian Springthorpe, Paul Willis, Simon Guile
  • Chemical compounds
    Patent number: 7709500
    Abstract: The invention provides compounds of formula (I): wherein: X is CH2, O, S(O)2 or NR10; Y is a bond, CH2, NR35, CH2NH, CH2NHC(O), CH(OH), CH(NHCOR33), CH(NHSO2R34), CH2O or CH2S; Z is C(O), or when Y is a bond Z can also be S(O)2; R1 is optionally substituted aryl, optionally substituted heterocyclyl or C4-6 cycloalkyl fused to a benzene ring; and R2, R3, R4, R5, R6, R7 and R8, R9, R10, R32, R33, R34 and R35 are as defined herein; are modulators of chemokine (especially CCR3) activity (for use in, for example, treating asthma). The invention also provides a process for making 4-(3,4-dichlorophenoxy)piperidine, which is useful as an intermediate for making certain compounds of the invention.
    Type: Grant
    Filed: February 17, 2003
    Date of Patent: May 4, 2010
    Assignee: AstraZeneca AB
    Inventors: Lilian Alcaraz, Mark Furber, Mark Purdie, Brian Springthorpe
  • Trisubstituted triazolopyrimidines for use in platelet aggregation inhibition
    Publication number: 20100069408
    Abstract: The invention provides new triazolo[4,5-d]pyrimidine compounds, their use as medicaments, compositions containing them and processes for their preparation.
    Type: Application
    Filed: November 18, 2009
    Publication date: March 18, 2010
    Applicant: AstraZeneca AB
    Inventors: David Hardern, Anthony Ingall, Brian Springthorpe, Paul Willis, Simon Guile
  • Piperidine Derivatives, Their Process for Preparation, Their Use as Therapeutic Agents and Pharmaceutical Compositions Containing Them
    Publication number: 20090197914
    Abstract: The present invention provides a compound of a formula (I) wherein the variables are defined herein; to a process for preparing such a compound; and to the use of such a compound in the treatment of a chemokine (such as CCR3) mediated disease state.
    Type: Application
    Filed: March 6, 2007
    Publication date: August 6, 2009
    Inventors: Peter Cage, Mark Furber, Matthew Perry, Brian Springthorpe
  • Chemical Compounds
    Publication number: 20090118513
    Abstract: The present invention provides a compound of a formula (I): wherein the variables are defined herein; to a process for preparing such a compound; and to the use of such a compound in the treatment of a chemokine (such as CCR3) or H1 mediated disease state.
    Type: Application
    Filed: January 15, 2009
    Publication date: May 7, 2009
    Applicant: AstraZeneca AB
    Inventors: Moya Caffrey, Christopher Luckhurst, Tobias Mochel, Matthew Perry, Brian Springthorpe
  • N-Benzyl-Morpholine Derivatives as Modulators of the Chemokine Receptor
    Publication number: 20090118288
    Abstract: The present invention provides a compound of a formula (I): wherein the variables are defined herein; to a process for preparing such a compound; and to the use of such a compound in the treatment of a chemokine (such as CCR3) mediated disease state.
    Type: Application
    Filed: July 19, 2006
    Publication date: May 7, 2009
    Applicant: ASTRAZENECA AB
    Inventors: Christopher Luckhurst, Brian Springthorpe
  • Piperidine derivatives useful as modulators of chemokine receptor activity
    Patent number: 7517989
    Abstract: The present invention provides a compound of formula (I), wherein: Z is (A) OR (B) and wherein the remaining variables are defined herein; to a process for preparing such a compound; and to the use of such a compound in the treatment of achemokine (such as CCR3) or H1 mediated disease state.
    Type: Grant
    Filed: March 17, 2003
    Date of Patent: April 14, 2009
    Assignee: AstraZeneca AB
    Inventors: Christopher Luckhurst, Matthew Perry, Hitesh Sanganee, Brian Springthorpe
  • Piperidine Derivatives Useful as Modulators of Chemokine Receptor Activity
    Publication number: 20090069325
    Abstract: The present invention relates to the compounds of formula (I): in which: and the remaining variables are defined herein. The present invention also relates to a process for preparing such compounds and use of such compounds in the treatment of a chemokine (such as CCR3) or H1 mediated disease state.
    Type: Application
    Filed: November 10, 2008
    Publication date: March 12, 2009
    Applicant: AstraZeneca AB
    Inventors: Christopher Luckhurst, Matthew Perry, Hitesh Sanganee, Brian Springthorpe
  • Chemical compounds
    Patent number: 7495013
    Abstract: The present invention relates to compounds of formula (I): The variables recited in formula (I) are defined in the specification. The present invention also relates to processes of preparing compounds of formula (I) and uses of such compounds for treating a chemokine (e.g., CCR3) or H1 mediated disease state.
    Type: Grant
    Filed: March 30, 2004
    Date of Patent: February 24, 2009
    Assignee: AstraZeneca AB
    Inventors: Moya Caffrey, Christopher Luckhurst, Tobias Mochel, Matthew Perry, Brian Springthorpe
  • Piperidine derivatives useful as modulators of chemokine receptor activity
    Patent number: 7482363
    Abstract: The present invention provides a compound of formula (I), wherein the variables are defined herein; to a process for preparing such a compound; and to the use of such a compound in the treatment of a chemokine (such as CCR3) or H1 mediated disease state.
    Type: Grant
    Filed: March 17, 2003
    Date of Patent: January 27, 2009
    Assignee: AstraZeneca AB
    Inventors: Hitesh Sanganee, Brian Springthorpe
  • Piperidine Derivatives, Their Process for Preparation, Their Use as Therapeutic Agents and Pharmaceutical Compositions Containing Them
    Publication number: 20090023733
    Abstract: The present invention provides a compound of a formula (I): [Chemical formula should be inserted here. Please see paper copy] wherein the variables are defined herein; to a process for preparing such a compound; and to the use of such a compound in the treatment of a chemokine (such as CCR3) mediated disease state.
    Type: Application
    Filed: March 6, 2007
    Publication date: January 22, 2009
    Inventors: Peter Cage, Mark Furber, Christopher Luckhurst, Matthew Perry, Brian Springthorpe
  • Piperidine Derivatives, Their Process for Preparation, Their Use as Therapeutic Agents and Pharmaceutical Compositions Containing Them
    Publication number: 20090012125
    Abstract: The present invention provides a compound of a formula (I): [Chemical formula should be inserted here. Please see paper copy] wherein the variables are defined herein; to a process for preparing such a compound; and to the use of such a compound in the treatment of a chemokine (such as CCR3) mediated disease state.
    Type: Application
    Filed: March 6, 2007
    Publication date: January 8, 2009
    Inventors: Peter Cage, Mark Furber, Tobias Mochel, Matthew Perry, Brian Springthorpe
  • Piperidines for the Treatment of Chemokine Mediated Diseases
    Publication number: 20080275084
    Abstract: The present invention provides a compound of a formula (I): wherein the variables are defined herein; to a process for preparing such a compound; and to the use of such a compound in the treatment of a chemokine (such as CCR3) or H1 mediated disease state.
    Type: Application
    Filed: May 24, 2006
    Publication date: November 6, 2008
    Applicant: ASTRAZENECA AB
    Inventors: Matthew Perry, Brian Springthorpe
  • Piperidine Derivatives for the Treatment of Chemokine Mediated Disease
    Publication number: 20080262037
    Abstract: The present invention provides a compound of a formula (I) wherein the variables are defined herein; to a process for preparing such a compound; and to the use of such a compound in the treatment of a chemokine (such as CCR3) or H1 mediated disease state.
    Type: Application
    Filed: April 5, 2005
    Publication date: October 23, 2008
    Applicant: ASTRAZENECA AB
    Inventors: Tobias Mochel, Matthew Perry, Brian Springthorpe
  • Triazolo(4,5-D)pyrimidine compounds
    Patent number: RE46276
    Abstract: Triazolo[4,5-d]pyrimidine compounds, their use as medicaments, compositions containing them and processes for their preparation. The compounds of the invention have the formula (I) as follows: wherein R, X and R1 through R3 are as defined in the specification.
    Type: Grant
    Filed: December 21, 2015
    Date of Patent: January 17, 2017
    Assignee: AstraZeneca UK Limited
    Inventors: David Hardem, Anthony Ingall, Brian Springthorpe, Paul Willis, Simon Guile